Iovance Biotherapeutics Inc (IOVA.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Iovance Biotherapeutics reports Q3 GAAP loss per share $0.35
- BRIEF-Iovance Biotherapeutics announces pricing of its public offering of $50 mln of common stock
- BRIEF-Iovance BioTherapeutics plans to offer $50 mln of common stock
- BRIEF-Iovance Biotherapeutics announces approval of 1st clinical trial of LN-145 for treating cervical cancer
- BRIEF-Iovance Biotherapeutics enters into a research collaboration with the Ohio State University Comprehensive Cancer Center